The Trump administration has sued drugmaker Gilead Sciences over sales of the HIV-prevention drug Truvada — a drug approved for daily use as PrEP to help prevent HIV-negative people from contracting HIV from a partner who is positive.
The government says the company is earning billions from research funded by taxpayers.
Host Jeremy Hobsons speaks with Kaiser Health News reporter Shefali Luthra (@shefalil).
This article was originally published on WBUR.org.
Copyright 2021 NPR. To see more, visit https://www.npr.org.